National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Cong XueLi Zhang

Abstract

Treatment choice for NSCLC in China has not previously been reported. This paper explores the clinical practice and adherence to treatment guidelines for NSCLC. A specifically designed questionnaire was used. It consisted of personal information of the responders and treatment details (patient identification data was excluded). Questionnaires were delivered to doctors in 12 major cities in China. Doctors were asked to answer the questionnaires based on real cases in their daily practice. 987 cases of NSCLC were included. In first-line chemotherapy, regimens were mostly platinum-based among which gemcitabine plus platinum was predominately used (27.4%), followed by docetaxel plus platinum (16.2%) and paclitaxel plus platinum (13.5%). In second-line therapy some were treated with single agents, such as docetaxel (12.9%), gefitinib (11.1%), pemetrexed (9.3%), and erlotinib (3.5%). 44.5% were with doublet therapy. Detection rate of epidermal growth factor receptor (EGFR) mutation was only 9.6% because of the limited prevalence of testing technology. EGFR mutation rate was 46.8%. EGFR-tyrosine kinase inhibitors (TKIs) were used more frequently as salvage (14.8%) rather than upfront therapy (5.3%). This survey reveals the daily clini...Continue Reading

References

Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnold L PotoskyCharles F Lynch
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott D RamseyBonnie Donato
Jun 2, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Cesare GridelliFilippo de Marinis
Jan 8, 2010·The New England Journal of Medicine·Milton C Weinstein, Jonathan A Skinner
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G D'AddarioUNKNOWN ESMO Guidelines Working Group
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
May 20, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Cesare GridelliFilippo De Marinis

❮ Previous
Next ❯

Citations

Jul 23, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hongyun Zhao, Li Zhang
Nov 8, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yasushi YatabeTony Mok
Jun 4, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yayi HeCaicun Zhou
Oct 12, 2013·International Journal of Cancer. Journal International Du Cancer·Zhan ZhangShou-Lin Wang
Aug 15, 2015·Thoracic Cancer·Yuankai Shi, Yan Sun
Dec 3, 2014·Drug Discovery Today·Yi-Long WuYumei Yang
Jul 2, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ting-Yuan David ChengMary E Reid
Nov 5, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yan ZhangYong Lin
May 30, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rui WanJie Wang
Mar 22, 2019·Personalized Medicine·Yuxian BaiShunchang Jiao
Sep 29, 2019·Journal of Clinical Laboratory Analysis·Baisong LouHong Chen
Feb 13, 2018·Experimental and Therapeutic Medicine·Guo-Jun GengXian-En Fa
Jan 31, 2017·Asia-Pacific Journal of Clinical Oncology·Yuankai ShiYu Huang
Apr 5, 2016·Asian Pacific Journal of Cancer Prevention : APJCP·Juan ZhouBin-Wu Ying

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.